Presenting at Biopartnering @JPM and H.C. Wainwright BioConnect
Actinogen CEO Dr Steven Gourlay will present at the Biopartnering @JPM associated with the 40th annual JP Morgan HealthCare Conference in San Francisco from 10 to 13 January 2022. While in San Francisco, Dr Gourlay will also present at the H.C. Wainwright BioConnect Virtual Conference that runs concurrently with the JP Morgan conference.
View ASX Announcement and presentations
Depression selected as our third disease program, expanding Fragile X Syndrome program and launches capital raising
We are pleased to announce several strategic initiatives. Major Depressive Disorder (MDD) selected as third indication for Xanamem, Phase 2 XanaFX clinical trial for patients with Fragile X Syndrome (FXS) expanded and launches capital raising.
View ASX Announcement
XanaMIA Part A trial achieves target enrolment
We are pleased to announce that target enrolment has been reached in the XanaMIA Part A trial of 105 participants and that results are expected in Q2 CY2022. Dr Steven Gourlay said "The completion of XanaMIA Part A enrolment is a significant milestone in the Company's program to evaluate its lead molecule, Xanamem, for Alzheimer's Disease, Fragile X Syndrome and Depression.”
View ASX Announcement
Strategic collaboration with Oxford University researchers
We are pleased to announce finalisation of a clinical protocol as part of a strategic collaboration with researchers at the Radcliffe Department of Medicine, University of Oxford, to investigate Xanamem and a condition called Mild Autonomous Cortisol Secretion (MACS).
View ASX Announcement

About Us

Actinogen Medical  (ACW) is an ASX-listed, biotechnology company developing an innovative treatment for cognitive impairment associated with neurological diseases amenable to modifications of raised cortisol levels inside brain cells. ‘Cognition’ relates to how a person understands and acts in the world around them. Cognitive functions include memory, reasoning, awareness and decision-making, and to a large extent, influence our personality.

Actinogen Medical’s lead drug candidate, Xanamem®has been specifically designed to block the production of cortisol – the stress hormone – in the brain. Chronically elevated cortisol is associated with cognitive decline in Alzheimer’s Disease, potentially linked to cognitive impairment and anxiety in Fragile X syndrome, and cognitive impairment in other diseases. 

Xanamem offers a promising new approach to treat cognitive impairment associated with these neurological diseases.

In the Company’s recent XanaHES Phase I trial, Xanamem exhibited a statistically significant improvement in cognition among healthy older volunteers treated with 20mg Xanamem daily, and recent human target engagement data for the drug in the brain suggests good activity of doses as low as 5mg daily. The Company is conducting a range of quality Phase II studies evaluating Xanamem in the treatment of cognitive impairment associated with Alzheimer’s disease, Fragile X syndrome, and other indication(s) with a strong scientific rationale.